summitplc.com Report : Visit Site

Technical data of the summitplc.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host summitplc.com. Currently, hosted in United States and its service provider is Merit Network Inc. .

the related websites

bloomberg.com moneyam.com bbc.co.uk holvita.co.uk walmart.com sparknotes.com britishfibroidtrust.org.uk nomorepanic.co.uk bestdirect.co.uk individualrestaurants.com medicalgasresearch.com meningitis.org 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

you are using an outdated browser. upgrade your browser today or install google chrome frame to better experience this site. home about overview and strategy board of directors executive management careers programmes c. difficile infection gonorrhoea discuva platform duchenne muscular dystrophy for the dmd community publications investors financial reports regulatory news sec filings agm 2018 events & presentations share information analyst coverage corporate information corporate governance shareholder notifications aim rule 26 advisers contacts media press releases webcasts & videos contacts contact summit therapeutics we are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs. our strategy focuses on infectious diseases, with a historical programme in rare diseases. our clinical programme targets the infectious disease caused by the bacteria c. difficile . summit therapeutics we are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs. our strategy focuses on infectious diseases, with a historical programme in rare diseases. our clinical programme targets the infectious disease caused by the bacteria c. difficile . summit therapeutics we are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs. our strategy focuses on infectious diseases, with a historical programme in rare diseases. our clinical programme targets the infectious disease caused by the bacteria c. difficile . latest news 2nd july 2018 summit therapeutics plc : holding(s) in company 2nd july 2018 summit therapeutics plc : holding(s) in company 27th june 2018 summit therapeutics announces phaseout dmd did not meet primary endpoint asm microbe 2018 click to view our asm presentations. share price lse: summ 38.50 p -1.00 at 03:00pm gmt 05 jul 2018 nasdaq: smmt $ 2.47 -0.13 at 04:00pm et 05 jul 2018 current programmes c. difficile infection clostridium difficile infection (‘cdi’) is a major healthcare issue in hospitals, long-term care homes, and increasingly in the wider community. it is a serious illness caused by infection of the colon by the bacteria, c. difficile, which produces toxins that cause inflammation, severe diarrhoea and can in the most serious of cases be fatal. read more gonorrhoea gonorrhoea has been identified as one of three urgent threats by the us centers for disease control and prevention (‘cdc’) and a high priority pathogen by the world health organisation. we are developing new mechanism antibiotics for the treatment of all gonorrhoea. read more email alerts disclaimer privacy policy site map copyright © summit therapeutics plc 2015 summit therapeutics plc, 136a eastern avenue, milton park, abingdon, oxfordshire, ox14 4sb company number 05197494 website design by carr kamasa design email alerts name email address company investor type institutional investor private investor analyst press/media employee other anti-spam question 1+1=? update on ezutromid after reviewing the top-line results of phaseout dmd, we have made the difficult decision to discontinue the development of ezutromid. we recognize that this decision will be disappointing for the duchenne community, but the data from phaseout dmd were clear that ezutromid, while well-tolerated, did not provide a benefit to patients with dmd. these results are not what we had hoped for, and certainly not what we had expected based on the encouraging interim results from phaseout dmd. but, they provide a clear answer to the important scientific question of ezutromid’s effect in dmd. the results provided no evidence that ezutromid is having a meaningful effect on slowing dmd progression. we therefore cannot support further development of ezutromid. we are now working with our clinical trial investigators to bring the phaseout dmd clinical trial and associated extension phase to a close. patients in phaseout dmd should contact their study doctors for more information. we sincerely thank the patients, families and clinical trial sites who have been involved in all of our clinical trials of ezutromid. we plan to explore ways that the information gathered as part of phaseout dmd can be made available to support other research activities in dmd for the benefit of the entire community. we are also grateful for the support that we’ve had from patient organizations worldwide in the development of ezutromid. we believe that the future of duchenne research is bright. there are numerous clinical trials and research studies taking place in this field, and there is hope on the horizon for all those living with dmd. if you have further questions, please contact michelle avery, phd, our director of patient engagement, at [email protected] . sincerely, glyn edwards, ceo of summit 7ads6x98y

URL analysis for summitplc.com

https://www.summitplc.com/investors/covering-analysts/
https://www.summitplc.com/contact/
https://www.summitplc.com/investors/regulatory-news/
https://www.summitplc.com/media/press-releases/
https://www.summitplc.com/investors/agm-2018/
https://www.summitplc.com/site-map
https://www.summitplc.com/programmes/gonorrhoea/
https://www.summitplc.com/about/careers/
https://www.summitplc.com/about/executive-management/
https://www.summitplc.com/media/contacts/
https://www.summitplc.com/disclaimer
https://www.summitplc.com/#inline1
https://www.summitplc.com/programmes/
https://www.summitplc.com/programmes/for-the-dmd-community/
https://www.summitplc.com/programmes/c-difficile-infections/
carrkamasa.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: SUMMITPLC.COM
Registry Domain ID: 954620034_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.ascio.com
Registrar URL: http://www.ascio.com
Updated Date: 2017-05-02T12:08:29Z
Creation Date: 2007-05-02T15:53:18Z
Registry Expiry Date: 2018-05-02T15:53:18Z
Registrar: Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA
Registrar IANA ID: 106
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +442070159370
Domain Status: ok https://icann.org/epp#ok
Name Server: DNSSEC1-WIN.SERVER.NTLI.NET
Name Server: DNSSEC2-WIN.SERVER.NTLI.NET
Name Server: NS1.VIRGINMEDIA.NET
Name Server: NS2.VIRGINMEDIA.NET
Name Server: NS3.VIRGINMEDIA.NET
Name Server: NS4.VIRGINMEDIA.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-26T00:39:07Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =summitplc.com

  PORT 43

  TYPE domain

DOMAIN

  NAME summitplc.com

  CHANGED 2017-05-02

  CREATED 2007-05-02

STATUS
ok https://icann.org/epp#ok

NSERVER

  DNSSEC1-WIN.SERVER.NTLI.NET 62.253.162.235

  DNSSEC2-WIN.SERVER.NTLI.NET 62.253.162.236

  NS1.VIRGINMEDIA.NET 62.253.162.237

  NS2.VIRGINMEDIA.NET 194.168.4.237

  NS3.VIRGINMEDIA.NET 62.253.162.37

  NS4.VIRGINMEDIA.NET 194.168.4.33

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .